RYZ101 Improves PFS in Phase 3 ACTION-1 Trial for GEP-NETs After Lutetium-177 Therapy / Actinium-225, ACTION-1 Trial, BMS, ...

The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...

Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for ...

A man in his 20s was pronounced deceased at the scene and another man in his 20s remains in a serious condition in hospital ...

Johnson & Johnson (NYSE:JNJ), the healthcare group, raised its 2026 sales and earnings forecasts after third-quarter sales grew 6% on an operational basis, supported by its medicines business and new ...

Bristol Myers Squibb ( NYSE: BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb ...

Turkish researchers tested fifteen machine learning models to predict chemotherapy response in metastatic colorectal cancer, ...

First clinical data for OAP-101, built on proprietary OmniAntigen™ Platform (OAP)OAP enables systematic immune reprogramming therapy (XIRT™) to overcome resistance of cold solid tumors to current ...

A St. Jude cohort study of 2,508 adult childhood cancer survivors finds that living in disadvantaged neighborhoods roughly ...

Viewers can submit questions live; the webcast replay will be posted two hours after the presentation and remain available ...

Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value ...

The pharma company is on track to reach $100 billion in recorded revenue despite “temporary” headwinds in its medtech segment ...